223 related articles for article (PubMed ID: 15322234)
1. Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.
Leontiou C; Lakey JH; Austin CA
Mol Pharmacol; 2004 Sep; 66(3):430-9. PubMed ID: 15322234
[TBL] [Abstract][Full Text] [Related]
2. Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.
Leontiou C; Lakey JH; Lightowlers R; Turnbull RM; Austin CA
Mol Pharmacol; 2006 Jan; 69(1):130-9. PubMed ID: 16239602
[TBL] [Abstract][Full Text] [Related]
3. Differential selection of acridine resistance mutations in human DNA topoisomerase IIbeta is dependent on the acridine structure.
Leontiou C; Watters GP; Gilroy KL; Heslop P; Cowell IG; Craig K; Lightowlers RN; Lakey JH; Austin CA
Mol Pharmacol; 2007 Apr; 71(4):1006-14. PubMed ID: 17209120
[TBL] [Abstract][Full Text] [Related]
4. Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.
Turnbull RM; Meczes EL; Perenna Rogers M; Lock RB; Sullivan DM; Finlay GJ; Baguley BC; Austin CA
Cancer Chemother Pharmacol; 1999; 44(4):275-82. PubMed ID: 10447574
[TBL] [Abstract][Full Text] [Related]
5. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
6. Yeast topoisomerase II mutants resistant to anti-topoisomerase agents: identification and characterization of new yeast topoisomerase II mutants selected for resistance to etoposide.
Liu YX; Hsiung Y; Jannatipour M; Yeh Y; Nitiss JL
Cancer Res; 1994 Jun; 54(11):2943-51. PubMed ID: 8187080
[TBL] [Abstract][Full Text] [Related]
7. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the gyrB domain of eukaryotic topoisomerase II can lead to partially dominant resistance to etoposide and amsacrine.
Nitiss JL; Vilalta PM; Wu H; McMahon J
Mol Pharmacol; 1994 Oct; 46(4):773-7. PubMed ID: 7969059
[TBL] [Abstract][Full Text] [Related]
9. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
10. Murine transgenic cells lacking DNA topoisomerase IIbeta are resistant to acridines and mitoxantrone: analysis of cytotoxicity and cleavable complex formation.
Errington F; Willmore E; Tilby MJ; Li L; Li G; Li W; Baguley BC; Austin CA
Mol Pharmacol; 1999 Dec; 56(6):1309-16. PubMed ID: 10570059
[TBL] [Abstract][Full Text] [Related]
11. mAMSA resistant human topoisomerase IIbeta mutation G465D has reduced ATP hydrolysis activity.
Gilroy KL; Leontiou C; Padget K; Lakey JH; Austin CA
Nucleic Acids Res; 2006; 34(5):1597-607. PubMed ID: 16549872
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/religation and sensitivity to the antineoplastic drugs etoposide and 4'-(9-acridinylamino)methane-sulfon-m-anisidide.
DeVore RF; Corbett AH; Osheroff N
Cancer Res; 1992 Apr; 52(8):2156-61. PubMed ID: 1313738
[TBL] [Abstract][Full Text] [Related]
13. A temperature sensitive topoisomerase II allele confers temperature dependent drug resistance on amsacrine and etoposide: a genetic system for determining the targets of topoisomerase II inhibitors.
Nitiss JL; Liu YX; Hsiung Y
Cancer Res; 1993 Jan; 53(1):89-93. PubMed ID: 8380128
[TBL] [Abstract][Full Text] [Related]
14. Altered topoisomerase IIalpha and multidrug resistance-associated protein levels during drug selection: adaptations to increasing drug pressure.
Matsumoto Y; Takano H; Nagao S; Fojo T
Jpn J Cancer Res; 2001 Sep; 92(9):968-74. PubMed ID: 11572765
[TBL] [Abstract][Full Text] [Related]
15. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Zwelling LA; Chan D; Hinds M; Mayes J; Silberman LE; Blick M
Cancer Res; 1988 Dec; 48(23):6625-33. PubMed ID: 2846155
[TBL] [Abstract][Full Text] [Related]
16. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
[TBL] [Abstract][Full Text] [Related]
17. Random mutagenesis of the B'A' core domain of yeast DNA topoisomerase II and large-scale screens of mutants resistant to the anticancer drug etoposide.
Jiang X
Biochem Biophys Res Commun; 2005 Feb; 327(2):597-603. PubMed ID: 15629155
[TBL] [Abstract][Full Text] [Related]
18. Increased sensitivity to quinolone antibacterials can be engineered in human topoisomerase IIalpha by selective mutagenesis.
Hammonds TR; Foster SR; Maxwell A
J Mol Biol; 2000 Jul; 300(3):481-91. PubMed ID: 10884345
[TBL] [Abstract][Full Text] [Related]
19. Analysis of yeast DNA topoisomerase II mutants resistant to the antitumor drug amsacrine.
Wasserman RA; Wang JC
Cancer Res; 1994 Apr; 54(7):1795-800. PubMed ID: 8137294
[TBL] [Abstract][Full Text] [Related]
20. Functional expression of human topoisomerase II alpha in yeast: mutations at amino acids 450 or 803 of topoisomerase II alpha result in enzymes that can confer resistance to anti-topoisomerase II agents.
Hsiung Y; Jannatipour M; Rose A; McMahon J; Duncan D; Nitiss JL
Cancer Res; 1996 Jan; 56(1):91-9. PubMed ID: 8548781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
